These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 28131770)

  • 1. Dopamine D3 receptor-modulated neuroprotective effects of lisuride.
    Kim M; Lee S; Cho J; Kim G; Won C
    Neuropharmacology; 2017 May; 117():14-20. PubMed ID: 28131770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
    Kim MK; Park HS; Cho JH; Kim GS; Won C
    Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
    Collo G; Zanetti S; Missale C; Spano P
    Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C; Papazoglou A; Just L; Nikkhah G
    Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture.
    Moldzio R; Radad K; Duvigneau JC; Kranner B; Krewenka C; Piskernik C; Rausch WD
    J Neural Transm (Vienna); 2006 Sep; 113(9):1095-105. PubMed ID: 16463121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
    Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
    Le WD; Jankovic J; Xie W; Appel SH
    J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.
    Das B; Rajagopalan S; Joshi GS; Xu L; Luo D; Andersen JK; Todi SV; Dutta AK
    Neuropharmacology; 2017 Sep; 123():88-99. PubMed ID: 28533164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
    Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
    J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration.
    Double KL; Halliday GM; Henderson J; Griffiths FM; Heinemann T; Riederer P; Gerlach M
    Exp Neurol; 2003 Nov; 184(1):530-5. PubMed ID: 14637122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.
    Newton CL; Wood MD; Strange PG
    PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
    Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
    Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.